Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study Group

Central nervous system (CNS) involvement is a rare and aggressive complication of multiple myeloma (MM). We identified 54/4352 MM patients (1.2%), who developed CNS‐MM between 2000 and 2022. A matched‐control group of MM patients without CNS‐MM was used for comparisons. Median age was 63 years. Medi...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2024-10, Vol.99 (10), p.1897-1905
Main Authors: Katodritou, Eirini, Dalampira, Dimitra, Delimpasi, Sosana, Ntanasis‐Stathopoulos, Ioannis, Karaolidou, Fryni, Gkioka, Annita‐Ioanna, Labropoulou, Vasiliki, Spanoudakis, Emmanouil, Triantafyllou, Theodora, Kotsopoulou, Maria, Michalis, Eyrydiki, Vadikolia, Chrysanthi, Papadopoulou, Theodosia, Sevastoudi, Aggeliki, Michael, Michael, Daiou, Aikaterini, Pentidou, Aikaterini, Kostopoulos, Ioannis, Palaska, Vasiliki, Gavriatopoulou, Maria, Kyrtsonis, Marie‐Christine, Verrou, Evgenia, Kastritis, Efstathios, Dimopoulos, Meletios‐Athanasios, Terpos, Evangelos
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Bortezomib
Case-Control Studies
Central nervous system
Central Nervous System Neoplasms - mortality
Central Nervous System Neoplasms - therapy
Cerebrospinal fluid
Chemotherapy
Cytogenetics
Female
Greece - epidemiology
Humans
Immunotherapy
L-Lactate dehydrogenase
Male
Meninges
Middle Aged
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Nervous system
Plasma cell leukemia
Prophylaxis
Retrospective Studies
Thalidomide
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Central nervous system (CNS) involvement is a rare and aggressive complication of multiple myeloma (MM). We identified 54/4352 MM patients (1.2%), who developed CNS‐MM between 2000 and 2022. A matched‐control group of MM patients without CNS‐MM was used for comparisons. Median age was 63 years. Median time to CNS‐MM was 28 months; 6/54 experienced CNS‐MM at MM diagnosis. Abnormal lactate dehydrogenase (LDH), high‐risk cytogenetics, and extramedullary involvement (EMI), that is, soft tissue plasmacytomas and/or plasma cell leukemia (PCL), were more frequent in CNS‐MM versus controls (p 
ISSN:0361-8609
1096-8652
1096-8652
DOI:10.1002/ajh.27425